

Takashi Kobayashi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5860696/publications.pdf>

Version: 2024-02-01

20
papers

511
citations

687363

13
h-index

794594

19
g-index

22
all docs

22
docs citations

22
times ranked

527
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of glutathione for the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, multicenter, pilot study. <i>BMC Gastroenterology</i> , 2017, 17, 96.	2.0	65
2	Direct Comparison of US and MR Elastography for Staging Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 908-917.e11.	4.4	57
3	Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001990.	2.8	53
4	Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan. <i>Journal of Gastroenterology</i> , 2021, 56, 1022-1032.	5.1	49
5	Endotoxins and Non-Alcoholic Fatty Liver Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 770986.	3.5	40
6	Diagnostic accuracy of FibroScan®-AST score to identify non-alcoholic steatohepatitis with significant activity and fibrosis in Japanese patients with non-alcoholic fatty liver disease: Comparison between M and XL probes. <i>Hepatology Research</i> , 2020, 50, 831-839.	3.4	32
7	The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8161.	4.1	29
8	Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2275-2284.	2.8	26
9	Autotaxin is a valuable biomarker for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 1136-1146.	3.4	24
10	Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 996-1007.	8.1	22
11	Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glyco-biomarker for non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2020, 10, 321.	3.3	21
12	Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , 2019, 49, 872-880.	3.4	19
13	Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. <i>Hepatology Communications</i> , 2022, 6, 2273-2285.	4.3	17
14	Vitamin B6 efficacy in the treatment of nonalcoholic fatty liver disease: an open-label, single-arm, single-center trial. <i>Journal of Clinical Biochemistry and Nutrition</i> , 2021, 68, 181-186.	1.4	13
15	Metabolomic/lipidomic-based analysis of plasma to diagnose hepatocellular ballooning in patients with non-alcoholic fatty liver disease: A multicenter study. <i>Hepatology Research</i> , 2020, 50, 955-965.	3.4	12
16	Effect of tofogliflozin and pioglitazone on hepatic steatosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A randomized, open-label pilot study (ToPiND study). <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100516.	1.1	11
17	Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial. <i>Cancers</i> , 2022, 14, 2112.	3.7	11
18	Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design. <i>Contemporary Clinical Trials</i> , 2018, 69, 40-47.	1.8	4

#	ARTICLE	IF	CITATIONS
19	Comparing the effectiveness of magnesium oxide and naldemedine in preventing opioid-induced constipation: a proof of concept, single institutional, two arm, open-label, phase II, randomized controlled trial: the MAGNET study. <i>Trials</i> , 2020, 21, 453.	1.6	4
20	Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake. <i>Oncologist</i> , 2021, 26, e1862-e1869.	3.7	2